Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1036 to 1050 of 1505 results for patients and public

  1. Donor milk banks: service operation (CG93)

    This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.

  2. Secca System for faecal incontinence (MIB66)

    NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence

  3. Artificial intelligence for analysing chest CT images (MIB243)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .

  4. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  5. Contraception: advice for people taking anti-seizure medication (IND78)

    This indicator covers the percentage of women under the age of 55 years who are taking antiseizure medications who have a record of information and counselling about contraception, conception and pregnancy in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM03

  6. AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)

    NICE has developed a medtech innovation briefing (MIB) on the AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis

  7. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

  8. Contraception: advice for people with epilepsy (IND117)

    This indicator covers the percentage of women with epilepsy who are aged 18 or over, but under 45, who are taking antiseizure medications and have a record of being given information and advice in the previous 12 months about pregnancy or conception, or contraception tailored to their pregnancy and contraceptive intentions. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM71

  9. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.

  10. Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)

    This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.

  11. Esketamine nasal spray for treatment-resistant depression (TA854)

    Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.

  12. Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)

    Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.